Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

Retrospective study (n=513) found eribulin use linked to objective response rate (ORR) of 54.4% and progression free survival (PFS) of 6.1 months overall. In those with triple negative breast cancer, the ORR and PFS were 55.1% and 5.8 months respectively.

Source:

Advances in Therapy